KALTF - Kalytera Therapeutics, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0175
-0.0055 (-23.91%)
At close: 3:52PM EST
Stock chart is not supported by your current browser
Previous Close0.0230
Open0.0220
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0175 - 0.0230
52 Week Range0.0162 - 0.0878
Volume240,265
Avg. Volume287,045
Market Cap8.893M
Beta (3Y Monthly)2.39
PE Ratio (TTM)N/A
EPS (TTM)-0.0290
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Kalytera Announces Closing of Final Tranche of Private Placement of Common Shares and Common Share Purchase Warrants and Amendments to Secured Convertible Debenture Units

    Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the “Company” or “Kalytera”) is pleased to announce that it has closed an additional and final tranche of its private placement, for 2,811,111 common shares of the Company and 2,811,111 common share purchase warrants for aggregate gross proceeds of approximately C$126,500. Industrial Alliance Securities Inc. will receive compensation in connection with this tranche of the private placement consisting of a cash commission equal to C$10,120 and will be issued 224,889 warrants bearing the same terms as those issued in the offering. All securities issued in this tranche are subject to a hold period expiring on February 26, 2020 in accordance with applicable securities laws.

  • GlobeNewswire

    Kalytera Provides Update on Private Placement of Common Shares and Common Share Purchase Warrants

    Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the “Company” or “Kalytera”) is pleased to announce that it has closed an additional tranche of its private placement, for 1,974,445 common shares of the Company and 1,974,445 common share purchase warrants for aggregate gross proceeds of approximately C$88,850.  All securities issued in this tranche are subject to a hold period expiring on February 17, 2020 in accordance with applicable securities laws.

  • GlobeNewswire

    Kalytera Terminates Plan to Acquire CBD Extraction Facility

    Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") has announced that, due to a decline in the market price for CBD isolate, it has decided not to proceed with its previously announced plan to acquire a majority interest in Oregon 01, LLC (“Oregon 01”), and has terminated its Letter of Intent (“LOI”) with Oregon 01. Under the LOI, Kalytera was to invest USD $3.5 million for the acquisition of a 51% interest in Oregon 01. The principal product that Oregon 01 planned to produce was CBD isolate extracted from hemp.

  • GlobeNewswire

    Kalytera Announces Notice of Allowance of EU Patent for Prevention and Treatment of Graft Versus Host Disease

    Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") is pleased to announce that the European Patent Office has issued a Notice of Allowance for EU Patent Application Number 14791611.8 covering the use of cannabidiol (“CBD”) in the treatment of graft versus host disease (“GVHD”). Kalytera has exclusive worldwide rights to this patent through an Exclusive License Agreement with MOR Research Applications, Ltd. of Israel. Securing a European patent for this proprietary technology represents an important step forward for Kalytera in its program to develop and commercialize CBD for prevention and treatment of this serious and life-threatening disease.

  • GlobeNewswire

    Kalytera Announces Closing of First Tranche of Private Placement of Common Shares and Common Share Purchase Warrants

    Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the “Company” or “Kalytera”) is pleased to announce the closing of the first tranche of its private placement, for 10,946,423 common shares of the Company and 10,946,423 common share purchase warrants for aggregate gross proceeds of C$505,084.38. Alere Financial Partners, a division of Cova Capital Partners LLC, acted as agent and as compensation will receive a cash commission equal to C$30,410.47 and will be issued 675,788 warrants bearing the same terms as those issued in the offering.  All securities issued in the offering are subject to a hold period expiring on January 14, 2020 in accordance with applicable securities laws.

  • GlobeNewswire

    Kalytera Announces Update to Private Placement

    SAN FRANCISCO and TEL AVIV, Israel, Sept. 11, 2019 -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that it is.

  • GlobeNewswire

    Kalytera Announces Interest Payment in Shares

    Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that it has elected to make an interest payment under the C$787,500 principal amount secured convertible debenture issued in a private placement on March 6, 2019 (the “Debenture”), through the issuance of common shares in the capital of the Company (“Common Shares”). The transaction is subject to approval by the TSX Venture Exchange (“TSXV”). The interest payment owing is in the amount of C$19,849.32.  This payment will be satisfied through the issuance of 396,987 Common Shares.  The number of Common Shares to be issued is based on a deemed issue price of C$0.05 per Common Share.

  • GlobeNewswire

    Kalytera Reports Second Quarter 2019 Financial Results

    SAN FRANCISCO and TEL AVIV, Israel, Aug. 29, 2019 -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today reported financial.

  • GlobeNewswire

    Kalytera Announces Management-Led Private Placement of Up To $1.5 Million of Common Shares and Common Share Purchase Warrants

    Proceeds of the Private Placement will be used to fund preparatory work for initiation of the Company’s Phase 3 clinical registration study for its lead product development program evaluating cannabidiol (“CBD”) for the prevention of acute graft versus host disease (“GVHD”). Proceeds will also be used to augment the Company’s working capital as it continues discussions with potential corporate partners for its GVHD program.

  • GlobeNewswire

    Kalytera to Conclude Phase 2 Clinical Study and Initiate Phase 3 Study

    Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that interim results from the Company’s Phase 2 clinical study evaluating cannabidiol (“CBD”) for the prevention of acute graft versus host disease (“GVHD”) are significantly positive, and, as a result, the Company will not enroll the high dose cohort in its ongoing Phase 2 study, but will instead proceed directly to initiate a Phase 3 clinical registration study. The Company’s Phase 2 clinical study was designed in accordance with input received from the U.S. FDA.

  • GlobeNewswire

    Kalytera Announces Results of Shareholder Meeting Votes

    Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the “Company” or “Kalytera”) announced today that shareholder votes on the election of directors, the approval of the Company’s auditors and the renewal of its Stock Option Plan were approved by the Company’s shareholders. The Company did not proceed with the shareholder vote with respect to the authorization of a potential share consolidation. Additional information regarding the Shareholder Meeting can be found in the Circular dated June 21, 2019, which was delivered to Kalytera shareholders and is available on the Company’s SEDAR profile.

  • GlobeNewswire

    Kalytera Will Not Proceed with Vote on Potential Share Consolidation

    Additional information regarding the Meeting can be found in the Circular dated June 21, 2019, which was delivered to Kalytera shareholders and is available on the Company’s SEDAR profile. Kalytera Therapeutics, Inc. is pioneering the development of a next generation of cannabinoid therapeutics.

  • GlobeNewswire

    Kalytera Announces Completion of Food Effect and QTc Study

    Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that it has completed Study KAL-07, the Food Effect and QTc Study, that is part of the Company’s product development program evaluating cannabidiol (“CBD”) for the prevention of acute graft versus host disease (“GVHD”). Preliminary results for the Food Effect and QTc Study are positive and as expected.

  • GlobeNewswire

    Kalytera to Hold Annual and Special Meeting on July 29, 2019

    SAN FRANCISCO and TEL AVIV, Israel, July 05, 2019 -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the “Company” or “Kalytera”) announced today that it is.

  • GlobeNewswire

    Kalytera to Acquire CBD Extraction Business

    Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the “Company” or “Kalytera”) announced today that it has signed a Letter of Intent (“LOI”) to acquire a majority interest in Oregon 01, LLC (doing business as “Clean Bi Design”), which will operate a hemp-based cannabidiol (“CBD”) extraction facility in Amity, Oregon. Under the LOI, Kalytera has agreed to invest USD $3.5 million for the acquisition of a 51% interest in the business. The extraction facility will be both GMP certified and FDA compliant, and equipped with state-of-the-art equipment for extraction, distillation and isolation.

  • GlobeNewswire

    Kalytera Provides Update on GVHD Program

    Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today provided an update on its lead product development program evaluating cannabidiol (“CBD”) for the prevention of acute graft versus host disease (“GVHD”). To date, the results of Kalytera’s Phase 2 clinical study have been positive and encouraging. No patients in the first (low dose) cohort developed grades 3 or 4 acute GVHD while receiving oral CBD treatment, and only one patient developed grade 2 acute GVHD.

  • GlobeNewswire

    Kalytera Announces Grant of Stock Options to Directors

    Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that it has granted stock options on June 19, 2019 to the directors of the Company.  The stock options have an exercise price of $0.05 per common share and expire ten years from the date of grant.  One third of the options granted will vest on June 19, 2020 and the remaining options will vest in twenty-four (24) equal monthly installments commencing July 2020. Stock options to purchase 68,698 common shares of Kalytera were granted to Ron Erickson, stock options to purchase 254,345 common shares were granted to Jeff Paley, and stock options to purchase 1,000,000 common shares were granted to Rob Hutchison, who very recently joined the Company’s board of directors.

  • GlobeNewswire

    Kalytera Announces Changes to Board of Directors

    Mr. Robin “Rob” Hutchison has joined the Board to fill the vacancy created by the resignation of Mr. Gary Leong, an independent director who also served on the Company’s Audit and Governance and Nominating Committees. Mr. Hutchison, who is an independent director, will also serve as a member of the Company’s Audit, Compensation and Governance and Nominating Committees.

  • GlobeNewswire

    Kalytera Announces Additional Progress with Cannabinoid-Based Compound for Treatment of Acute and Chronic Pain

    Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that it has invented a novel first-in-class cannabinoid molecule, designated KAL-1816, that strongly and selectively binds with and activates the alpha3 glycine pain receptor. Activation of the alpha3 glycine receptor shuts down pain transmission in inflammatory conditions, such as arthritis, colitis, and sciatica. “Today’s announcement is a milestone in Kalytera’s search for a breakthrough cannabinoid analgesic that will operate via a wholly new pathway,” stated Robert Farrell, Kalytera’s President and CEO.

  • GlobeNewswire

    Kalytera Reports First Quarter 2019 Financial Results

    Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today reported financial results for the first quarter of 2019. “Since the beginning of the year, we have made important progress in our lead product development program," stated Robert Farrell, Kalytera’s President and CEO. In the first quarter (“Q1”) of 2019, the Company recorded a net loss of approximately $6.4 million ($0.021 per Common Share), compared with a net loss of approximately $1.9 million ($0.01 per Common Share) in Q1 2018.

  • GlobeNewswire

    Kalytera Announces Submission of Patent Application to the U.S. Patent and Trademark Office

    Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that it has filed a provisional patent application with the United States Patent and Trademark Office (“USPTO”) covering Kalytera’s novel compositions of cannabidiol (“CBD”) in combination with certain metabolites of the human microbiome as a potential treatment for ulcerative colitis, Crohn’s disease, inflammatory bowel disease (“IBD”), graft versus host disease (“GVHD”) and other GI tract inflammatory diseases.

  • GlobeNewswire

    Kalytera Announces Data Further Elucidating CBD’s Mechanisms of Action in Prevention of GVHD

    Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced new laboratory findings demonstrating that cannabidiol (“CBD”) acts through a distinct biological pathway to restore epithelial cell tight junction integrity, which is highly important in preventing acute graft versus host disease (“GVHD”) and associated comorbidities. Acute GVHD is a life-threatening complication commonly occurring after bone marrow transplant procedures. Prior to the bone marrow transplant, patients typically undergo a total body irradiation (“TBI”) procedure.

  • GlobeNewswire

    Kalytera Announces Engagement of Echelon Wealth Partners to Assist with Review of Potential Out-License Opportunities for Commercial Rights to GVHD Products

    Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") has engaged Echelon Wealth Partners to determine the value, on a risk-adjusted basis, of its cannabidiol ("CBD") therapeutic products for the prevention and treatment of graft versus host disease ("GVHD"), and to assist with the review of potential out-licensing opportunities for the commercial rights to these products. Kalytera has recently received unsolicited inquiries from companies interested in the rights to Kalytera’s GVHD products, and, in response to these inquiries, Kalytera’s board of directors approved the engagement of Echelon.

  • GlobeNewswire

    Kalytera Therapeutics, Inc. Announces Second Closing of Public Offering

    Any failure to comply with this restriction may constitute a violation of U.S. Securities laws. SAN FRANCISCO and TEL AVIV, Israel, May 14, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX Venture: KLY) (KALTF) (the “Company” or “Kalytera”) is pleased to announce the second closing of its previously announced public offering (the “Offering”) of units of the Company (“Units”) for aggregate gross proceeds of CDN$1,617,500.

  • GlobeNewswire

    Kalytera Reports 2018 Financial Results

    Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today reported financial results for the year ended December 31 2018. Investors should note that the Company’s TSXV ticker symbol was recently changed from "KALY" to "KLY". For 2018, the Company recorded net income of approximately $6.9 million ($0.04 per Common Share), compared with a net loss of approximately $31.9 million ($0.26 per Common Share) in 2017.